Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Greenwich Lifesciences Inc (GLSI)

Greenwich Lifesciences Inc (GLSI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 405,813
  • Shares Outstanding, K 13,855
  • Annual Sales, $ 0 K
  • Annual Income, $ -15,790 K
  • EBIT $ -20 M
  • EBITDA $ -20 M
  • 60-Month Beta 1.47
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 184.01

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.32
  • Number of Estimates 2
  • High Estimate -0.30
  • Low Estimate -0.34
  • Prior Year -0.61
  • Growth Rate Est. (year over year) +47.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.00 +187.80%
on 12/16/25
32.91 -12.55%
on 01/14/26
+18.47 (+179.15%)
since 12/15/25
3-Month
7.78 +269.92%
on 11/24/25
32.91 -12.55%
on 01/14/26
+18.45 (+178.61%)
since 10/15/25
52-Week
7.78 +269.92%
on 11/24/25
32.91 -12.55%
on 01/14/26
+16.31 (+130.79%)
since 01/15/25

Most Recent Stories

More News
The $69B Precision Pivot: Why Biomarker Platforms are Igniting a New Oncology Gold Rush

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – The genomics in cancer care market is on a massive tear, projected to hit $69.16 billion by 2032 as doctors...

ONCY : 0.9981 (-4.94%)
BCT.TO : 6.30 (-6.53%)
ACRV : 1.8700 (+2.19%)
LLY : 1,031.11 (-3.93%)
BCTX : 4.53 (-6.79%)
GLSI : 28.70 (-2.01%)
CATX : 2.48 (-5.34%)
Greenwich LifeSciences Extends Lock-up of Directors and Officers to September 30, 2026

STAFFORD, Texas, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,...

GLSI : 28.70 (-2.01%)
Greenwich LifeSciences Provides Additional Updates on FLAMINGO-01 and Corporate Strategy

STAFFORD, Texas, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,...

GLSI : 28.70 (-2.01%)
Greenwich LifeSciences Announces Preliminary Analysis Showing 80% Recurrence Rate Reduction in the Open Label Arm of FLAMINGO-01

STAFFORD, Texas, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,...

GLSI : 28.70 (-2.01%)
Greenwich LifeSciences Announces Completion of Enrollment in the Open Label Arm of FLAMINGO-01 

STAFFORD, Texas, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,...

GLSI : 28.70 (-2.01%)
Greenwich LifeSciences Provides Global Update on FLAMINGO-01, Screening Over 1,000 Patients to Date

STAFFORD, Texas, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,...

GLSI : 28.70 (-2.01%)
Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Belgium

STAFFORD, Texas, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,...

GLSI : 28.70 (-2.01%)
Greenwich LifeSciences Announces Addition of Portugal to Flamingo-01 Clinical Trial

STAFFORD, Texas, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,...

GLSI : 28.70 (-2.01%)
Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Ireland

STAFFORD, Texas, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,...

GLSI : 28.70 (-2.01%)
Greenwich LifeSciences’ GLSI-100 Granted US FDA Fast Track Designation

STAFFORD, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,...

GLSI : 28.70 (-2.01%)

Business Summary

Greenwich LifeSciences Inc. is a clinical stage biopharmaceutical company focuses on the development of cancer immunotherapies for breast cancer and other human epidermal growth factor. The company's product candidate includes GP2, which is in clinical stage. Greenwich LifeSciences Inc.is based in Stafford,...

See More

Key Turning Points

3rd Resistance Point 36.42
2nd Resistance Point 34.66
1st Resistance Point 31.98
Last Price 28.70
1st Support Level 27.54
2nd Support Level 25.78
3rd Support Level 23.10

See More

52-Week High 32.91
Last Price 28.70
Fibonacci 61.8% 23.31
Fibonacci 50% 20.34
Fibonacci 38.2% 17.38
52-Week Low 7.78

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar